Literature DB >> 23673861

Complex formation with nucleic acids and aptamers alters the antigenic properties of platelet factor 4.

Miriam E Jaax1, Krystin Krauel, Thomas Marschall, Sven Brandt, Julia Gansler, Birgitt Fürll, Bettina Appel, Silvia Fischer, Stephan Block, Christiane A Helm, Sabine Müller, Klaus T Preissner, Andreas Greinacher.   

Abstract

The tight electrostatic binding of the chemokine platelet factor 4 (PF4) to polyanions induces heparin-induced thrombocytopenia, a prothrombotic adverse drug reaction caused by immunoglobulin G directed against PF4/polyanion complexes. This study demonstrates that nucleic acids, including aptamers, also bind to PF4 and enhance PF4 binding to platelets. Systematic assessment of RNA and DNA constructs, as well as 4 aptamers of different lengths and secondary structures, revealed that increasing length and double-stranded segments of nucleic acids augment complex formation with PF4, while single nucleotides or single-stranded polyA or polyC constructs do not. Aptamers were shown by circular dichroism spectroscopy to induce structural changes in PF4 that resemble those induced by heparin. Moreover, heparin-induced anti-human-PF4/heparin antibodies cross-reacted with human PF4/nucleic acid and PF4/aptamer complexes, as shown by an enzyme immunoassay and a functional platelet activation assay. Finally, administration of PF4/44mer-DNA protein C aptamer complexes in mice induced anti-PF4/aptamer antibodies, which cross-reacted with murine PF4/heparin complexes. These data indicate that the formation of anti-PF4/heparin antibodies in postoperative patients may be augmented by PF4/nucleic acid complexes. Moreover, administration of therapeutic aptamers has the potential to induce anti-PF4/polyanion antibodies and a prothrombotic diathesis.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23673861      PMCID: PMC3709655          DOI: 10.1182/blood-2013-01-478966

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  47 in total

1.  Plasma DNA as a prognostic marker in trauma patients.

Authors:  Y M Lo; T H Rainer; L Y Chan; N M Hjelm; R A Cocks
Journal:  Clin Chem       Date:  2000-03       Impact factor: 8.327

2.  Glucosamine sulfate does not crossreact with the antibodies of patients with heparin-induced thrombocytopenia.

Authors:  G Weimann; N Lubenow; K Selleng; P Eichler; D Albrecht; A Greinacher
Journal:  Eur J Haematol       Date:  2001-03       Impact factor: 2.997

3.  Heparin is not required for detection of antibodies associated with heparin-induced thrombocytopenia/thrombosis.

Authors:  G P Visentin; M Moghaddam; S E Beery; J G McFarland; R H Aster
Journal:  J Lab Clin Med       Date:  2001-07

4.  Delayed-onset heparin-induced thrombocytopenia.

Authors:  Lawrence Rice; Walid K Attisha; Alane Drexler; John L Francis
Journal:  Ann Intern Med       Date:  2002-02-05       Impact factor: 25.391

5.  DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells.

Authors:  S Jahr; H Hentze; S Englisch; D Hardt; F O Fackelmayer; R D Hesch; R Knippers
Journal:  Cancer Res       Date:  2001-02-15       Impact factor: 12.701

6.  Pharmacokinetics and safety of an anti-vascular endothelial growth factor aptamer (NX1838) following injection into the vitreous humor of rhesus monkeys.

Authors:  D W Drolet; J Nelson; C E Tucker; P M Zack; K Nixon; R Bolin; M B Judkins; J A Farmer; J L Wolf; S C Gill; R A Bendele
Journal:  Pharm Res       Date:  2000-12       Impact factor: 4.200

7.  Platelet alpha-granule proteins: studies on release and subcellular localization.

Authors:  K L Kaplan; M J Broekman; A Chernoff; G R Lesznik; M Drillings
Journal:  Blood       Date:  1979-04       Impact factor: 22.113

8.  The severity of trauma determines the immune response to PF4/heparin and the frequency of heparin-induced thrombocytopenia.

Authors:  Norbert Lubenow; Peter Hinz; Simone Thomaschewski; Theresia Lietz; Michael Vogler; Andrea Ladwig; Michael Jünger; Matthias Nauck; Sebastian Schellong; Kathrin Wander; Georg Engel; Axel Ekkernkamp; Andreas Greinacher
Journal:  Blood       Date:  2009-11-20       Impact factor: 22.113

9.  Time course of early and late changes in plasma DNA in trauma patients.

Authors:  Nicole Y L Lam; Timothy H Rainer; Lisa Y S Chan; Gavin M Joynt; Y M Dennis Lo
Journal:  Clin Chem       Date:  2003-08       Impact factor: 8.327

10.  Conditional gene expression by controlling translation with tetracycline-binding aptamers.

Authors:  Beatrix Suess; Shane Hanson; Christian Berens; Barbara Fink; Renée Schroeder; Wolfgang Hillen
Journal:  Nucleic Acids Res       Date:  2003-04-01       Impact factor: 16.971

View more
  47 in total

1.  Pharmacogenetics to prevent heparin-induced thrombocytopenia: what do we know?

Authors:  Jason H Karnes
Journal:  Pharmacogenomics       Date:  2018-11-06       Impact factor: 2.533

Review 2.  Induction of anti-PF4/heparin antibodies after arthroplasty for rheumatic diseases.

Authors:  Kiyoshi Migita; Tomoyuki Asano; Shuzo Sato; Satoru Motokawa
Journal:  Fukushima J Med Sci       Date:  2018-04-07

3.  Neutrophil accumulation and NET release contribute to thrombosis in HIT.

Authors:  Kandace Gollomp; Minna Kim; Ian Johnston; Vincent Hayes; John Welsh; Gowthami M Arepally; Mark Kahn; Michele P Lambert; Adam Cuker; Douglas B Cines; Lubica Rauova; M Anna Kowalska; Mortimer Poncz
Journal:  JCI Insight       Date:  2018-09-20

4.  B-cell tolerance regulates production of antibodies causing heparin-induced thrombocytopenia.

Authors:  Yongwei Zheng; Alexander W Wang; Mei Yu; Anand Padmanabhan; Benjamin E Tourdot; Debra K Newman; Gilbert C White; Richard H Aster; Renren Wen; Demin Wang
Journal:  Blood       Date:  2013-12-19       Impact factor: 22.113

5.  Polyphosphate/platelet factor 4 complexes can mediate heparin-independent platelet activation in heparin-induced thrombocytopenia.

Authors:  Douglas B Cines; Serge V Yarovoi; Sergei V Zaitsev; Tatiana Lebedeva; Lubica Rauova; Mortimer Poncz; Gowthami M Arepally; Sanjay Khandelwal; Victoria Stepanova; Ann H Rux; Adam Cuker; Cecilia Guo; Linnette Mae Ocariza; Richard J Travers; Stephanie A Smith; Hugh Kim; James H Morrissey; Edward M Conway
Journal:  Blood Adv       Date:  2016-11-22

6.  Platelet-Specific Chemokines Contribute to the Pathogenesis of Acute Lung Injury.

Authors:  Khalil Bdeir; Kandace Gollomp; Marta Stasiak; Junjie Mei; Izabela Papiewska-Pajak; Guohua Zhao; G Scott Worthen; Douglas B Cines; Mortimer Poncz; M Anna Kowalska
Journal:  Am J Respir Cell Mol Biol       Date:  2017-02       Impact factor: 6.914

7.  Distinct specificity and single-molecule kinetics characterize the interaction of pathogenic and non-pathogenic antibodies against platelet factor 4-heparin complexes with platelet factor 4.

Authors:  Rustem I Litvinov; Serge V Yarovoi; Lubica Rauova; Valeri Barsegov; Bruce S Sachais; Ann H Rux; Jillian L Hinds; Gowthami M Arepally; Douglas B Cines; John W Weisel
Journal:  J Biol Chem       Date:  2013-10-04       Impact factor: 5.157

8.  Mechanical prophylaxis is a heparin-independent risk for anti-platelet factor 4/heparin antibody formation after orthopedic surgery.

Authors:  Seiji Bito; Shigeki Miyata; Kiyoshi Migita; Mashio Nakamura; Kazuhito Shinohara; Tomotaro Sato; Takeharu Tonai; Motoyuki Shimizu; Yasuhiro Shibata; Kazuhiko Kishi; Chikara Kubota; Shinnosuke Nakahara; Toshihito Mori; Kazuo Ikeda; Shusuke Ota; Takeshi Minamizaki; Shigeru Yamada; Naofumi Shiota; Masataka Kamei; Satoru Motokawa
Journal:  Blood       Date:  2015-12-09       Impact factor: 22.113

Review 9.  Advances in the pathophysiology and treatment of heparin-induced thrombocytopenia.

Authors:  Steven E McKenzie; Bruce S Sachais
Journal:  Curr Opin Hematol       Date:  2014-09       Impact factor: 3.284

Review 10.  Heparin induced thrombocytopenia in critically ill: Diagnostic dilemmas and management conundrums.

Authors:  Sachin Gupta; Ravindranath Tiruvoipati; Cameron Green; John Botha; Huy Tran
Journal:  World J Crit Care Med       Date:  2015-08-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.